Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 77,000 Shares of Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 77,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the transaction, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at approximately $955,945.32. This trade represents a 52.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oric Pharmaceuticals Stock Performance

Oric Pharmaceuticals stock opened at $13.24 on Friday. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.93. The company has a 50-day simple moving average of $11.85 and a 200-day simple moving average of $10.73. The firm has a market capitalization of $1.37 billion, a P/E ratio of -9.81 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, sell-side analysts forecast that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ORIC. Citigroup reduced their price objective on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Stifel Nicolaus began coverage on Oric Pharmaceuticals in a research note on Friday, June 12th. They set a “buy” rating and a $14.00 target price on the stock. HC Wainwright boosted their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, The Goldman Sachs Group upgraded Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Friday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.45.

Institutional Trading of Oric Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new position in shares of Oric Pharmaceuticals in the first quarter valued at approximately $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after acquiring an additional 3,131 shares during the period. Goldman Sachs Group Inc. raised its holdings in Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock worth $1,645,000 after purchasing an additional 24,778 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Oric Pharmaceuticals by 1,331.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock worth $2,841,000 after purchasing an additional 473,600 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Oric Pharmaceuticals by 56.0% in the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock worth $174,000 after purchasing an additional 11,198 shares during the period. 95.05% of the stock is owned by institutional investors and hedge funds.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.